Los pacientes que recibieron el nuevo tratamiento vivieron una mediana de 13.2 meses, en comparación con 6.7 meses para quienes recibieron quimioterapia

The therapy is a brand new targeted drug for the disease which experts have labelled as a substantial breakthrough following doubling of survival time in a trial.

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer.

Daraxonrasib dobra a sobrevida após quimioterapia